Zenklusen, Isabelle http://orcid.org/0000-0002-8106-8087
Dingemanse, Jasper http://orcid.org/0000-0002-4083-5817
Reh, Christian
Gehin, Martine http://orcid.org/0000-0003-0780-1073
Kaufmann, Priska http://orcid.org/0000-0003-2415-3012
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects
https://doi.org/10.1007/s40268-024-00456-8
Funding for this research was provided by:
Idorsia Pharmaceuticals
Article History
Accepted: 14 January 2024
First Online: 13 March 2024
Declarations
:
: The study was funded by Idorsia Pharmaceuticals Ltd.
: During the conduct of this study, Isabelle Zenklusen, Jasper Dingemanse, Martine Gehin, and Priska Kaufmann were employees at Idorsia Pharmaceuticals Ltd and Christian Reh was the principal investigator.
: The study was conducted in full conformity with the principles of the Declaration of Helsinki. The protocol was approved by the German Health Authority (BfArM) and by the local independent Ethics Committee (Ethik Kommission der Bayerischen Landesärztekammer).
: All subjects provided written informed consent prior to any study procedure.
: Not applicable.
: The datasets generated and/or analyzed during the study are available from the corresponding author on reasonable request.
: Not applicable.
: IZ wrote the manuscript, IZ, JD, and MG designed the study, PK and JD analyzed the study, and CR was the principal investigator of the study. All authors revised the manuscript critically for important intellectual content and approved the version to be submitted.